Abstract:Introduction Vulvodynia is a complex and multifactorial medical condition characterized by pain and discomfort in the vulvar and vaginal area without any identifiable cause. Despite its prevalence, vulvodynia remains underdiagnosed, especially in the United States, leading to delayed diagnosis, increased risk of sexual dysfunction, and reduced quality of life. Concurrently, irritable bowel syndrome (IBS) is a gastrointestinal disorder with a global prevalence predominantly affecting women. Vulvodynia and IBS frequently co-occur in women, with a 2 to 4-fold increased likelihood of IBS diagnosis in those with vulvodynia (1). These comorbid conditions may share common underlying causes, highlighting the need for comprehensive research to better understand the underlying molecule mechanisms and develop effective management strategies. Recognizing the interplay between vulvodynia and IBS is crucial for improving women's health and well-being. Objective The aim of this review was to assess the evidence and mechanism of simultaneous presentation of IBS and vulvodynia, and whether the incidence of one condition predicts the incidence or increases susceptibility of the other condition. Additionally, this review aims to assess whether treating one condition impacts the presentation, prognosis, or outcome of the other. Methods A systematic search was conducted in 6 electronic databases: PubMed, Web of Science, Scopus, Science Direct, Google Scholar, and Cochrane Library (publication dates between January 1950 and August 2023). Primary research about the overlap of presentation, diagnosis, or treatment of IBS and vulvodynia was included. Data were extracted from eligible studies, summarized, and collated. Results Of the 306 unique articles identified, 38 were included in the final analysis: 33 were cross-sectional studies, along with 2 case reports, 1 open-label non-comparative study, 1 cohort study, and 1 nested case-control study. The data represents patients from 21 countries. Common themes amongst the studies included a hypothesis of central hypersensitization which can manifest as either and/or both vulvodynia and IBS, the incidence of vulvodynia being higher in younger and older women (women in their mid-40s had the lowest odds), the significant diagnostic delay in vulvodynia, and the need for a multimodal treatment strategy. Conclusions Our review adds to the evidence that there is a pervasive association with vulvodynia and IBS. Despite this, research on the underlying molecular mechanisms of the association is scarce, and diagnostic delays persist for vulvodynia. Increasing awareness of the overlap of these conditions will improve screening for vulvodynia in the IBS patient population, therefore improving the diagnostic delay. Further studies over longer time periods, and utilizing randomized study designs are needed to elucidate the mechanism of simultaneous presentation of IBS and vulvodynia, and how we can leverage their pathophysiology clinically to optimize diagnosis and treatment. Disclosure No.

A Perspective on the Interaction Between Recurrent Lower Urinary Tract Infections and Irritable Bowel Syndrome

Associations between Gut Microbiota Dysbiosis and Other Risk Factors in Women with a History of Urinary Tract Infections

Psychological Factors May Affect the Quality of Life in Irritable Bowel Syndrome Patients More Than the Gut Itself? A Multicenter Cross‐sectional Study

Characteristics Associated With Recurrent Urinary Tract Infections: A Case-Control Study

Intestinal Microecology and Quality of Life in Irritable Bowel Syndrome Patients

Association Between Allergic Diseases And Irritable Bowel Syndrome: A Retrospective Study

Gut–Brain Axis, Microbiota and Probiotics—Current Knowledge on Their Role in Irritable Bowel Syndrome: A Review

(029) Investigating The Overlapping Presentation Of Irritable Bowel Syndrome And Vulvodynia: A Systematic Review Of The Evidence And Mechanisms

The Current Evidence on the Association Between the Urinary Microbiome and Urinary Incontinence in Women

Gender-specific insights into the irritable bowel syndrome pathophysiology. Focus on gut dysbiosis and permeability

A51 ROLE OF GUT MICROBIOTA IN THE EPISODIC NATURE OF SYMPTOMS IN IRRITABLE BOWEL SYNDROME

Microbiome and Its Role in Irritable Bowel Syndrome

The Latest Data Concerning the Etiology and Pathogenesis of Irritable Bowel Syndrome

Exploration of associations among dietary tryptophan, microbiome composition and function, and symptom severity in irritable bowel syndrome

Gut Microbiota and Irritable Bowel Syndrome: Status and Prospect

Microbiome Shifts and Their Impact on Gut Physiology in Irritable Bowel Syndrome

A265 TEMPORAL DYNAMICS OF SYMPTOMS AND GUT MICROBIOTA IN EPISODES OF IRRITABLE BOWEL SYNDROME

Differential Urinary Microbiota Composition Between Women with and Without Recurrent Urinary Tract Infection

Microbiota in Irritable Bowel Syndrome and Endometriosis: Birds of a Feather Flock Together-A Review

Gut microbiome, diet and symptom interactions in irritable bowel syndrome

Probiotics, Prebiotics, and Synbiotics: Implications and Beneficial Effects Against Irritable Bowel Syndrome